Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

ClinicalTrials.gov ID: NCT00357500

Public ClinicalTrials.gov record NCT00357500. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Anti-Angiogenic Chemotherapy: A Phase II Trial of the Oral 5-Drug Regimen (Thalidomide, Celecoxib, Fenofibrate, Etoposide and Cyclophosphamide) in Patients With Relapsed or Progressive Cancer

Study identification

NCT ID
NCT00357500
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Dana-Farber Cancer Institute
Other
Enrollment
101 participants

Conditions and interventions

Interventions

  • celecoxib Drug
  • cyclophosphamide Drug
  • etoposide Drug
  • fenofibrate Drug
  • thalidomide Drug

Drug

Eligibility (public fields only)

Age range
Up to 21 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2004
Primary completion
Jan 31, 2013
Completion
Nov 30, 2013
Last update posted
Sep 30, 2014

2005 – 2013

United States locations

U.S. sites
10
U.S. states
10
U.S. cities
10
Facility City State ZIP Site status
Connecticut Children's Medical Center Hartford Connecticut 06106
Miami Children's Hospital Miami Florida 33155-4069
Children's Memorial Hospital - Chicago Chicago Illinois 60614
Maine Medical Center Research Institute Scarborough Maine 04074-7205
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Boston Massachusetts 02115
Children's Hospitals and Clinics of Minnesota - Minneapolis Minneapolis Minnesota 55404
St. Louis Children's Hospital St Louis Missouri 63110
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick New Jersey 08903
NYU Cancer Institute at New York University Medical Center New York New York 10016
Hasbro Children's Hospital Providence Rhode Island 02903

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00357500, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 30, 2014 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00357500 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →